中医药在核苷(酸)类似物治疗慢性乙型肝炎中的作用

王晗笑; 陈欣菊; 赵晴; 赵文霞

doi:10.3969/j.issn.1001-5256.2022.08.033

中医药在核苷(酸)类似物治疗慢性乙型肝炎中的作用

DOI: 10.3969/j.issn.1001-5256.2022.08.033

王晗笑¹,
陈欣菊²,
赵晴²,
赵文霞^2, , ,

1.
河南中医药大学第一临床医学院，郑州 450000
2.
河南中医药大学第一附属医院脾胃肝胆科，郑州 450000

基金项目:

2018年艾滋病和病毒性肝炎等重大传染病防治专项 (2018ZX10303502)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：王晗笑负责查找文献，撰写文章；陈欣菊、赵晴负责课题设计，修改文章；赵文霞负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
赵文霞，zhao-wenxia@163.com

计量
- 文章访问数: 447
- HTML全文浏览量: 124
- PDF下载量: 82
- 被引次数: 0
出版历程
- 收稿日期: 2021-12-03
- 录用日期: 2022-01-13
- 出版日期: 2022-08-20

Role of traditional Chinese medicine in treatment of chronic hepatitis B by nucleos(t)ide analogues

1.
The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou 450000, China
2.
Department of Hepatology and Spleen-Stomach, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China

Research funding:

National Science and Technology Major Project on Prevention and Treatment of Major Infectious Diseases such as AIDS and Viral Hepatitis (2018ZX10303502)

More Information

Corresponding author: ZHAO Wenxia, zhao-wenxia@163.com(ORCID:0000-0001-6549-6754)

摘要

摘要: 核苷(酸)类似物可抑制HBV复制，有效治疗慢性乙型肝炎，却无法彻底根除HBV，无法阻止低病毒载量下乙型肝炎肝硬化、肝癌的发展。近年来中药在慢性乙型肝炎的治疗中应用广泛，阐述了中药抑制HBV复制，降低HBeAg含量，延缓乙型肝炎肝硬化、肝癌发展等方面的应用及机制，提出中医药可提高核苷(酸)类似物治疗慢性乙型肝炎的疗效。
- 乙型肝炎, 慢性 /
- 肝硬化 /
- 癌, 肝细胞 /
- 核苷酸类 /
- 中草药
Abstract: Nucleos(t)ide analogues (NUC) can inhibit the replication of hepatitis B virus (HBV) and effectively treat chronic hepatitis B (CHB), but they cannot completely eradicate HBV and cannot prevent the progression to hepatitis B cirrhosis and liver cancer in the context of a low viral load. In recent years, traditional Chinese medicine has been widely used in the treatment of CHB. This article elaborates on the application and mechanism of traditional Chinese medicine in inhibiting HBV replication, reducing the content of HBeAg, and delaying the progression to hepatitis B cirrhosis, and it is proposed that traditional Chinese medicine can improve the therapeutic effect of NUC in the treatment of CHB.
- Hepatitis B, Chronic /
- Liver Cirrhosis /
- Carcinoma, Hepatocellular /
- Nucleotides /
- Drugs, Chinese Herbal

HTML全文

参考文献(60)

[1]	SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013[J]. Lancet, 2015, 386(10003): 1546-1555. DOI: 10.1016/S0140-6736(15)61412-X.
[2]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[3]	OTT JJ, HORN J, KRAUSE G, et al. Time trends of chronic HBV infection over prior decades - A global analysis[J]. J Hepatol, 2017, 66(1): 48-54. DOI: 10.1016/j.jhep.2016.08.013.
[4]	FISCHER KP, GUTFREUND KS, TYRRELL DL. Lamivudine resistance in hepatitis B: Mechanisms and clinical implications[J]. Drug Resist Updat, 2001, 4(2): 118-128. DOI: 10.1054/drup.2001.0190.
[5]	SYLVESTER-ARMSTRONG KR, DUFF P. Evidence for use of tenofovir in pregnancy to prevent perinatal transmission of hepatitis B infection[J]. Clin Obstet Gynecol, 2019, 62(4): 835-845. DOI: 10.1097/GRF.0000000000000438.
[6]	XIANG Q, LIU Z, YU Y, et al. Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report[J]. BMC Pharmacol Toxicol, 2020, 21(1): 43. DOI: 10.1186/s40360-020-00421-6.
[7]	QIAN YY, DAI ZJ, RUAN LY, et al. Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible?[J]. Drug Des Devel Ther, 2019, 13: 1127-1133. DOI: 10.2147/DDDT.S192632.
[8]	LEE WC, WU TH, WANG YC, et al. Renal function improvement by telbivudine in liver transplant recipients with chronic kidney disease[J]. Biomed Res Int, 2017, 2017: 9324310. DOI: 10.1155/2017/9324310.
[9]	REN JB, WANG Y, LI HY, et al. Telbivudine-associated creatine kinase elevation in chronic hepatitis B patients[J]. Chin J Hepatol, 2012, 20(9): 641-643. DOI: 10.3760/cma.j.issn.1007-3418.2012.09.001. 任江波, 王宇, 李红艺, 等. 替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析[J]. 中华肝脏病杂志, 2012, 20(9): 641-643. DOI: 10.3760/cma.j.issn.1007-3418.2012.09.001.
[10]	LIAN JS, ZHANG XL, LU YF, et al. Switching lamivudine with adefovir dipivoxil combination therapy to entecavir monotherapy provides better viral suppression and kidney safety[J]. Int J Med Sci, 2019, 16(1): 17-22. DOI: 10.7150/ijms.28700.
[11]	LIM YS, GWAK GY, CHOI J, et al. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial[J]. J Hepatol, 2019, 71(1): 35-44. DOI: 10.1016/j.jhep.2019.02.021.
[12]	CHARLTON MR, ALAM A, SHUKLA A, et al. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia[J]. J Gastroenterol, 2020, 55(9): 811-823. DOI: 10.1007/s00535-020-01698-4.
[13]	LUCIFORA J, PROTZER U. Attacking hepatitis B virus cccDNA—The holy grail to hepatitis B cure[J]. J Hepatol, 2016, 64(1 Suppl): S41-S48. DOI: 10.1016/j.jhep.2016.02.009.
[14]	KO C, CHAKRABORTY A, CHOU WM, et al. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels[J]. J Hepatol, 2018, 69(6): 1231-1241. DOI: 10.1016/j.jhep.2018.08.012.
[15]	SHIN EC, SUNG PS, PARK SH. Immune responses and immunopathology in acute and chronic viral hepatitis[J]. Nat Rev Immunol, 2016, 16(8): 509-523. DOI: 10.1038/nri.2016.69.
[16]	SUSLOV A, MEIER MA, KETTERER S, et al. Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity[J]. J Hepatol, 2021, 74(4): 794-800. DOI: 10.1016/j.jhep.2020.11.003.
[17]	TANG R, LEI Z, WANG X, et al. Hepatitis B envelope antigen increases Tregs by converting CD4⁺CD25^- T cells into CD4⁺CD25⁺Foxp3⁺Tregs[J]. Exp Ther Med, 2020, 20(4): 3679-3686. DOI: 10.3892/etm.2020.9107.
[18]	CHEN M, SÄLLBERG M, HUGHES J, et al. Immune tolerance split between hepatitis B virus precore and core proteins[J]. J Virol, 2005, 79(5): 3016-3027. DOI: 10.1128/JVI.79.5.3016-3027.2005.
[19]	WANG H, LUO H, WAN X, et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection[J]. J Hepatol, 2020, 72(1): 45-56. DOI: 10.1016/j.jhep.2019.08.024.
[20]	SU TH, LIU CJ. Combination therapy for chronic hepatitis B: Current updates and perspectives[J]. Gut Liver, 2017, 11(5): 590-603. DOI: 10.5009/gnl16215.
[21]	HIGASHI T, FRIEDMAN SL, HOSHIDA Y. Hepatic stellate cells as key target in liver fibrosis[J]. Adv Drug Deliv Rev, 2017, 121: 27-42. DOI: 10.1016/j.addr.2017.05.007.
[22]	WANG ML, WU DB, TAO YC, et al. The truncated mutant HBsAg expression increases the tumorigenesis of hepatitis B virus by regulating TGF-β/Smad signaling pathway[J]. Virol J, 2018, 15(1): 61. DOI: 10.1186/s12985-018-0972-0.
[23]	SONG J, ZHANG X, GE Q, et al. CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells[J]. J Cell Biochem, 2018, 119(10): 8419-8431. DOI: 10.1002/jcb.27050.
[24]	KANDA T, WU S, SASAKI R, et al. HBV core protein enhances cytokine production[J]. Diseases, 2015, 3(3): 213-220. DOI: 10.3390/diseases3030213.
[25]	RUAN Q, WANG H, BURKE LJ, et al. Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma[J]. Int J Cancer, 2020, 147(6): 1519-1527. DOI: 10.1002/ijc.32899.
[26]	BAGLIERI J, BRENNER DA, KISSELEVA T. The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma[J]. Int J Mol Sci, 2019, 20(7): 1723. DOI: 10.3390/ijms20071723.
[27]	WU Q, ZHOU L, LV D, et al. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression[J]. J Hematol Oncol, 2019, 12(1): 53. DOI: 10.1186/s13045-019-0739-0.
[28]	HU B, LIN JZ, YANG XB, et al. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review[J]. Cell Prolif, 2020, 53(3): e12772. DOI: 10.1111/cpr.12772.
[29]	Hepatobiliary Specialized Committee of China Association of Chinese Medicine, Liver Diseases Specialized Committee of China Medical Association of Minorities. The clinical guidelines of diagnosis and treatment of chronic hepatitis B with traditional Chinese medicine(2018)[J]. J Clin Hepatol, 2018, 34(12): 2520-2525. DOI: 10.3969/j.issn.1001-5256.2018.12.007. 中华中医药学会肝胆病专业委员会, 中国民族医药学会肝病专业委员会. 慢性乙型肝炎中医诊疗指南(2018年版)[J]. 临床肝胆病杂志, 2018, 34(12): 2520-2525. DOI: 10.3969/j.issn.1001-5256.2018.12.007.
[30]	LIU S, MA XB. Introduction of Professor Ma Xiaobei' s experience in the treatment of chronic hepatitis B[J]. Chin Med Herald, 2020, 17 (21): 169-172. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202021044.htm 刘沙, 马晓北. 马晓北教授治疗慢性乙型病毒性肝炎经验介绍[J]. 中国医药导报, 2020, 17 (21): 169-172. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202021044.htm
[31]	ZHU XJ, ZHANG X, ZHOU ZH, et al. The Lingmao Formula suppresses the replication of hepatitis B virus by enhancing innate immune response[J]. Chin J Integr Tradit West Med Liver Dis, 2018, 28(1): 33-36. DOI: 10.3969/j.issn.1005-0264.2018.01.012. 朱晓骏, 张鑫, 周振华, 等. 灵猫方通过增强天然免疫功能抑制乙型肝炎病毒复制的研究[J]. 中西医结合肝病杂志, 2018, 28(1): 33-36. DOI: 10.3969/j.issn.1005-0264.2018.01.012.
[32]	LIU XL, XIONG YQ, ZHOU DQ, et al. Influence of Bushenqingtou Decoction on serum IL-2, IL-4, IL-10, TNF-α and IFN-γin chronic hepatitis B patients with positive HBeAg[J]. Int J Lab Med, 2014, 35(5): 565-566, 571. DOI: 10.3969/j.issn.1673-4130.2014.05.024. 刘心亮, 熊益群, 周大桥, 等. 补肾清透方对慢性乙肝HBeAg阳性患者血清IL-2、IL-4、IL-10、TNF-α及IFN-γ的影响[J]. 国际检验医学杂志, 2014, 35(5): 565-566, 571. DOI: 10.3969/j.issn.1673-4130.2014.05.024.
[33]	FENG J, HUANG J, LI Z. Kushenin combined with adefovir dipivoxil affects the HBV-DNA load in serum, immune functions and liver functions of patients with chronic hepatitis B[J]. Exp Ther Med, 2017, 14(6): 5837-5842. DOI: 10.3892/etm.2017.5266.
[34]	WANG T, WANG X, ZHUO Y, et al. Antiviral activity of a polysaccharide from Radix Isatidis (Isatis indigotica Fortune) against hepatitis B virus (HBV) in vitro via activation of JAK/STAT signal pathway[J]. J Ethnopharmacol, 2020, 257: 112782. DOI: 10.1016/j.jep.2020.112782.
[35]	WEI ZQ, ZHANG YH, KE CZ, et al. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation[J]. World J Gastroenterol, 2017, 23(34): 6252-6260. DOI: 10.3748/wjg.v23.i34.6252.
[36]	RAHMAN MA, UEDA K, HONDA T. A Traditional chinese medicine, maoto, suppresses hepatitis B virus production[J]. Front Cell Infect Microbiol, 2020, 10: 581345. DOI: 10.3389/fcimb.2020.581345.
[37]	LE F, ZHANG X, ZHU XJ, et al. Effects of Bushen Jianpi Recipe on NKT cell function in positive HBeAg chronic hepatitis B patients after entecavir treatment[J]. Acta Univ Tradit Med Sin Pharmacol Shanghai, 2018, 32(3): 22-27. DOI: 10.16306/j.1008-861x.2018.03.005. 乐凡, 张鑫, 朱晓骏, 等. 补肾健脾方对恩替卡韦经治HBeAg阳性慢性乙型肝炎患者NKT细胞功能的影响[J]. 上海中医药大学学报, 2018, 32(3): 22-27. DOI: 10.16306/j.1008-861x.2018.03.005.
[38]	ZHANG X, LIU YH, XIE X, et al. Clinical study of Zi Ye Dan capsule combined with Enticavir for HBeAg positive chronic hepatitis B patients[J]. Chin J Integr Tradit West Med Liver Dis, 2020, 30(4): 292-295. DOI: 10.3969/j.issn.1005-0264.2020.04.002. 张鑫, 刘岩红, 鉏曦, 等. 紫叶丹胶囊治疗恩替卡韦经治的HBeAg阳性慢性乙型肝炎患者的临床研究[J]. 中西医结合肝病杂志, 2020, 30(4): 292-295. DOI: 10.3969/j.issn.1005-0264.2020.04.002.
[39]	LU YP, ZHOU DQ, XIONG YQ, et al. Effect of dendritic cells and HBV-DNA to chronic hepatitis B patients with Liangxue Zishen Yiqi method[J]. Chin J Exp Med Formul, 2015, 21(13): 160-164. DOI: 10.13422/j.cnki.syfjx.2015130160. 鲁艳平, 周大桥, 熊益群, 等. 凉血滋肾益气法对慢性乙肝患者树突状细胞和HBV-DNA的影响[J]. 中国实验方剂学杂志, 2015, 21(13): 160-164. DOI: 10.13422/j.cnki.syfjx.2015130160.
[40]	LI XK, ZHANG MX, SHAO FZ, et al. Adefovir dipivoxil plus Chinese medicine in HBeAg-positive chronic hepatitis B patients: A randomized controlled 48-week trial[J]. Chin J Integr Med, 2020, 26(5): 330-338. DOI: 10.1007/s11655-020-3250-0.
[41]	LI X, ZHOU D, CHI X, et al. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial[J]. Hepatol Int, 2020, 14(6): 985-996. DOI: 10.1007/s12072-020-10097-z.
[42]	YANG H, ZHOU Z, HE L, et al. Hepatoprotective and inhibiting HBV effects of polysaccharides from roots of Sophora flavescens[J]. Int J Biol Macromol, 2018, 108: 744-752. DOI: 10.1016/j.ijbiomac.2017.10.171.
[43]	XU H, LIU L, CHEN Y, et al. The chemical character of polysaccharides from processed Morindae officinalis and their effects on anti-liver damage[J]. Int J Biol Macromol, 2019, 141: 410-421. DOI: 10.1016/j.ijbiomac.2019.08.213.
[44]	LIU S, SHAO MY, MIAO ZM, et al. Effect of Ganlong Capsule on HBV transfected HepG2.2.15 cells and its mechanism[J]. Lishizhen Med Mater Med Res, 2020, 31(12): 2877- 2880. DOI: 10.3969/j.issn.1008-0805.2020.12.016. 刘姗, 邵明园, 缪志敏, 等. 肝龙胶囊对HBV转染的HepG2.2.15细胞的作用及其机制[J]. 时珍国医国药, 2020, 31(12): 2877- 2880. DOI: 10.3969/j.issn.1008-0805.2020.12.016.
[45]	PENG DT, XING YF, CHEN L, et al. Clinical study of Ruangan Granules combined with Entecavir in the treatment of severe hepatitis B fibrosis[J]. Lishizhen Medicine and Materia Medica Research, 2019, 30(8): 1934-1936. DOI: 10.3969/j.issn.1008-0805.2019.08.050. 彭得倜, 邢宇锋, 陈亮, 等. 软肝颗粒联合恩替卡韦治疗乙肝重度肝纤维化的临床研究[J]. 时珍国医国药, 2019, 30(8): 1934-1936. DOI: 10.3969/j.issn.1008-0805.2019.08.050.
[46]	GU HT, GUI HL, XU LM, et al. Clinical effect of Fuzheng Huayu tablets combined with entecavir in the treatment of chronic hepatitis B liver fibrosis[J]. J Clinl Hepatol, 2021, 37(2): 309-313. DOI: 10.3969/j.issn.1001-5256.2021.02.013. 顾宏图, 桂红莲, 徐列明, 等. 扶正化瘀片联合恩替卡韦治疗慢性乙型肝炎肝纤维化的效果观察[J]. 临床肝胆病杂志, 2021, 37(2): 309-313. DOI: 10.3969/j.issn.1001-5256.2021.02.013.
[47]	CHEN XN, LI SF, YUAN C. Clinical efficacy and safety of Taohong Huazhuo Decoction combined with entecavir on chronic hepatitis B cirrhosis (damp-heat accumulation syndrome)[J/CD]. Chin J Liver Dis(Electronic Version), 2021, 13(3): 9-15. DOI: 10.3969/j.issn.1674-7380.2021.03.002. 陈香妮, 李淑芳, 袁超. 桃红化浊汤联合恩替卡韦治疗慢性乙型肝炎肝硬化(湿热蕴结证)临床疗效及安全性[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(3): 9-15. DOI: 10.3969/j.issn.1674-7380.2021.03.002.
[48]	TIAN Y, WU S, DENG SS. Effect of Fuzheng Huayu capsule combined with antiviral drugs in treatment of hepatitis B cirrhosis and ratio index of glutamate transaminase-platelet[J]. Chin Arch Tradit Chin Med, 2021, 39(7): 176-179. DOI: 10.13193/j.issn.1673-7717.2021.07.044. 田琰, 武胜, 邓双双. 扶正化瘀胶囊结合抗病毒药物治疗乙型肝炎肝硬化效果及对谷草转氨酶-血小板比值指数的影响[J]. 中华中医药学刊, 2021, 39(7): 176-179. DOI: 10.13193/j.issn.1673-7717.2021.07.044.
[49]	MA X, ZHANG W, JIANG Y, et al. Paeoniflorin, a natural product with multiple targets in liver diseases-A mini review[J]. Front Pharmacol, 2020, 11: 531. DOI: 10.3389/fphar.2020.00531.
[50]	LAN T, ZHUANG L, LI S, et al. Polydatin attenuates hepatic stellate cell proliferation and liver fibrosis by suppressing sphingosine kinase 1[J]. Biomed Pharmacother, 2020, 130: 110586. DOI: 10.1016/j.biopha.2020.110586.
[51]	WANG R, SONG F, LI S, et al. Salvianolic acid A attenuates CCl₄-induced liver fibrosis by regulating the PI3K/AKT/mTOR, Bcl-2/Bax and caspase-3/cleaved caspase-3 signaling pathways[J]. Drug Des Devel Ther, 2019, 13: 1889-1900. DOI: 10.2147/DDDT.S194787.
[52]	JIANG C, IWAISAKO K, CONG M, et al. Traditional Chinese medicine Fuzheng Huayu prevents development of liver fibrosis in mice[J]. Arch Clin Biomed Res, 2020, 4(5): 561-580. DOI: 10.26502/acbr.50170125.
[53]	CHEN XQ, ZHANG PG, CHEN XR, et al. Effects of Fuzheng Xiaoliu granule on the expression of VEGF and HIF-1α in serum of primary hepatocellular carcinoma and its clinical significance[J]. World Sci Technol Modern Tradit Chin Med, 2020, 22(10): 3629-3635. DOI: 10.11842/wst.20190612004. 陈晓琦, 张鹏鸽, 陈新蕊, 等. 扶正消瘤颗粒对原发性肝癌血清中VEGF、HIF-1α表达的影响及临床意义[J]. 世界科学技术-中医药现代化, 2020, 22(10): 3629-3635. DOI: 10.11842/wst.20190612004.
[54]	LIU YG, NAN R, LI JT, et al. Clinical study of Yipi Yanggan decoction combined with percutaneous radiofrequency ablation in treating hepatitis B-related small liver cancer[J]. J Guangzhou Univ Tradit Chin Med, 2021, 38(2): 223-229. DOI: 10.13359/j.cnki.gzxbtcm.2021.02.001. 刘永刚, 南然, 李京涛, 等. 益脾养肝方联合经皮射频消融术治疗乙型肝炎相关小肝癌的临床研究[J]. 广州中医药大学学报, 2021, 38(2): 223-229. DOI: 10.13359/j.cnki.gzxbtcm.2021.02.001.
[55]	CHAI F, WU CR, ZHANG XY, et al. Therapeutic effect of entecavir combined with traditional Chinese medicine injection on advanced liver cancer patients complicated with hepatitis B virus infection and impact on prognosis[J]. Chin J Nosocomiol, 2017, 27(13): 2916-2919. DOI: 10.11816/cn.ni.2017-170767. 柴芳, 吴承容, 张小毅, 等. 恩替卡韦联合中药注射液对中晚期肝癌合并乙型肝炎病毒感染患者的疗效及预后的影响[J]. 中华医院感染学杂志, 2017, 27(13): 2916-2919. DOI: 10.11816/cn.ni.2017-170767.
[56]	WANG KX, DU GH, QIN XM, et al. Compound Kushen Injection intervenes metabolic reprogramming and epithelial-mesenchymal transition of HCC via regulating β-catenin/c-Myc signaling[J]. Phytomedicine, 2021, 93: 153781. DOI: 10.1016/j.phymed.2021.153781.
[57]	HUANG D, YANG B, YAO Y, et al. Autophagic inhibition of caveolin-1 by compound phyllanthus urinaria L. activates ubiquitination and proteasome degradation of β-catenin to suppress metastasis of hepatitis B-associated hepatocellular carcinoma[J]. Front Pharmacol, 2021, 12: 659325. DOI: 10.3389/fphar.2021.659325.
[58]	GUO W, HUANG J, WANG N, et al. Integrating network pharmacology and pharmacological evaluation for deciphering the action mechanism of herbal formula zuojin pill in suppressing hepatocellular carcinoma[J]. Front Pharmacol, 2019, 10: 1185. DOI: 10.3389/fphar.2019.01185.
[59]	FENG XY, CHEN BC, LI JC, et al. Gansui-Banxia Decoction extraction inhibits MDSCs accumulation via AKT /STAT3/ERK signaling pathways to regulate antitumor immunity in C57bl/6 mice[J]. Phytomedicine, 2021, 93: 153779. DOI: 10.1016/j.phymed.2021.153779.
[60]	LI X, YU H, GONG Y, et al. Fuzheng Xiaozheng prescription relieves rat hepatocellular carcinoma through improving anti-inflammation capacity and regulating lipid related metabolisms[J]. J Ethnopharmacol, 2022, 284: 114801. DOI: 10.1016/j.jep.2021.114801.